Immutep reported positive mature overall survival data from the INSIGHT-003 clinical trial in first-line non-small cell lung cancer (NSCLC). The company also provided an update regarding the TACTI-004 clinical trial. Immutep is a biotechnology company focused on developing immunotherapy treatments.
